# A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct07301229/  
OnCo record `nct07301229` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Shanghai Henlius Biotech, not yet recruiting.

## Summary

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer is a phase 2, randomised interventional study registered as NCT07301229 by Shanghai Henlius Biotech, with a registry enrolment figure of 100 participants, started 2025-12-29 and due to reach its primary completion in 2028-02-21. Interventions recorded: HLX43 DOSE 1 (2.5 mg/kg); HLX43 DOSE 2 (3.0 mg/kg). Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC). Primary outcome: ORR; PFS. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed, unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC),who has failed at least one prior line of standard systemic therapy". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07301229
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Pancreatic Cancer
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07301229: https://clinicaltrials.gov/study/NCT07301229

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07301229.json